Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. on June 3, 2026, covering events occurring on May 29, 2026. The company, incorporated in Delaware, operates in the longevity and regenerative medicine sectors, focusing on its cenplacel-L product and Lifebank cellular banking platform.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and strategic updates rather than financial performance data.
Material Changes
- Executive Appointment: On May 29, 2026, Rick Gonzalez was appointed as Chief Commercial Officer, reporting directly to Chairman and CEO Robert J. Hariri, M.D., Ph.D.
- Compensation Status: No definitive employment agreement has been entered into with Mr. Gonzalez at the time of this filing. Material terms of any compensatory arrangement will be disclosed in a subsequent filing.
- Strategic Focus: A shareholder letter issued on June 3, 2026, reiterated the company's strategic focus on longevity, regenerative medicine, and the preservation of human performance.
Guidance, Outlook, and Risks
Management commentary via a shareholder letter highlights the commercial opportunity for cenplacel-L and the Lifebank platform. The filing does not contain specific financial guidance, numerical outlooks, or new risk factors beyond standard operational disclosures. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the terms of the definitive employment agreement for Rick Gonzalez in future filings.
- Review the full text of the shareholder letter (Exhibit 99.2) for detailed strategic updates.
- Monitor upcoming financial reports (10-Q or 10-K) for quantitative performance metrics, as none are included in this 8-K.